Literature DB >> 1990224

Antibacterial effects of fibrin glue-antibiotic mixtures.

H B Kram1, M Bansal, O Timberlake, W C Shoemaker.   

Abstract

In the present in vitro study, we investigated the duration of action and antibacterial effects of nonautologous fibrin glue (FG) combined with antibiotics (Abs) including Ciprofloxacin, Teicoplanin, Cefoxitin, and Gentamicin; the effect of FG alone on bacterial growth was also evaluated. The rate of Ab diffusion from combined FG-Ab clots was evaluated by separate elution with pooled human serum (HS) and normal saline (NS); supernatants were removed daily and assayed for active concentrations of each Ab. The effects of FG and combined FG-Ab clots on bacterial growth were evaluated by inoculating brain-heart infusion (BHI) with Staphylococcus aureus, followed by the addition of FG or FG-Ab clots; a separate set of studies was also performed with the addition of mouse lung homogenate (MLH) as well. The addition of Ab to FG clots resulted in continuous diffusion of the Ab into the surrounding HS or NS for up to 5 to 7 days; however, more than two-thirds of the Ab diffused out within 2 to 3 days regardless of the Ab used. The antibacterial effects of FG-Ciprofloxacin and FG-Teicoplanin clots were significant compared to those of FG clots not containing Ab. In addition, the presence of FG clots (in BHI) resulted in a reduction in bacterial growth compared to that of BHI alone. The addition of MLH to BHI resulted in increased bacterial growth, but this effect was inhibited by the presence of combined FG-Ab clots.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1990224     DOI: 10.1016/0022-4804(91)90243-f

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  8 in total

1.  Fibrin glue.

Authors:  H I Atrah
Journal:  BMJ       Date:  1994-04-09

2.  In vitro degradation and drug release of a biodegradable tissue adhesive based on functionalized 1,2-ethylene glycol bis(dilactic acid) and chitosan.

Authors:  Claudia Lurtz; Karsten Voss; Veronika Hahn; Frieder Schauer; Juergen Wegmann; Erich K Odermatt; Klaus-Peter Schmitz; Katrin Sternberg
Journal:  J Mater Sci Mater Med       Date:  2012-12-30       Impact factor: 3.896

3.  Treatment of prosthetic valve endocarditis complicated by destruction of the aortic annulus.

Authors:  Yuki Okamoto; Kenji Minakata; Tomoyuki Yunoki; Masatake Katsu; Shin-ichiro Chino; Masahiko Matsumoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-08-18

4.  Use of fibrin sealants for the localized, controlled release of cefazolin.

Authors:  Stephen Tredwell; John K Jackson; Donald Hamilton; Vivian Lee; Helen M Burt
Journal:  Can J Surg       Date:  2006-10       Impact factor: 2.089

5.  Subverting bacterial resistance using high dose, low solubility antibiotics in fibrin.

Authors:  C J Woolverton; K Huebert; B Burkhart; M MacPhee
Journal:  Infection       Date:  1999 Jan-Feb       Impact factor: 3.553

6.  Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.

Authors:  B J McGrath; S L Kang; G W Kaatz; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

7.  Impact of local and systemic antimicrobials on leukocyte- and platelet rich fibrin: an in vitro study.

Authors:  S A M Siawasch; C Andrade; A B Castro; W Teughels; A Temmerman; M Quirynen
Journal:  Sci Rep       Date:  2022-02-17       Impact factor: 4.379

8.  A novel antimicrobial coating to prevent periprosthetic joint infection.

Authors:  Rita Ramalhete; Robyn Brown; Gordon Blunn; John Skinner; Melanie Coathup; Ian Graney; Anita Sanghani-Kerai
Journal:  Bone Joint Res       Date:  2020-12       Impact factor: 4.410

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.